# A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM

> **NCT07142161** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Nanjing Bioheng Biotech Co., Ltd.** · enrollment: 3 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** RD13-02 cell infusion

## Key facts

- **NCT ID:** NCT07142161
- **Lead sponsor:** Nanjing Bioheng Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-20
- **Primary completion:** 2026-07-24
- **Final completion:** 2026-12-25
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07142161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07142161, "A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07142161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*